Sharemaestro Newsreel

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

Alkermes plc reported break-even earnings for Q2 2026, surpassing the Zacks Consensus Estimate of a loss, while revenues of $496 million beat estimates. The company saw a 27% increase in total revenues year-over-year, driven by strong proprietary product sales, yet its stock declined in …

Piper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00

Piper Sandler has increased its price target for Teva Pharmaceutical Industries (NYSE:TEVA) to $44.00 from $42.00, maintaining an "overweight" rating and suggesting a potential upside of over 40% from its current price. This follows a trend of positive analyst sentiment, with a consensus "Moderate …

Regencell Bioscience Holdings Ltd (RGC) Cash Flow

This article provides an overview of Regencell Bioscience Holdings Ltd's (RGC) cash flow, including operating, investing, and financing cash flow, along with free cash flow. It details the company's operating cash flow for fiscal 2025, its year-over-year change, and capital expenditures for the most …

Cumberland Pharmaceuticals (CPIX) Projected to Announce Earnings on Tuesday

Cumberland Pharmaceuticals (CPIX) is expected to release its Q2 2026 earnings before the market opens on Tuesday, August 4th, with analysts forecasting a loss of $0.13 per share and revenue of $8.50 million. The company's previous quarter saw it meet loss estimates while exceeding …

Avoiding Lag: Real-Time Signals in (ANIK) Movement

An article by Stock Traders Daily's Quantitative Research Desk suggests that Anika Therapeutics Inc. (NASDAQ: ANIK) is facing weak near and mid-term sentiment, despite a positive long-term outlook. The analysis highlights a 34.4:1 risk-reward short setup, projecting a 10.9% downside risk versus a 0.3% …

How Ani Pharmaceuticals Inc. (ANIP) Affects Rotational Strategy Timing

The article analyzes Ani Pharmaceuticals Inc. (ANIP) through quantitative research, highlighting a near-term neutral sentiment amidst mid and long-term weakness. It details specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with defined entry points, targets, and stop losses. The analysis also provides multi-timeframe signal insights, …

OrganiGram Holdings Inc (OGI) Cash Flow

This article provides a detailed cash flow statement for OrganiGram Holdings Inc (OGI), presenting quarterly and annual data for operating, investing, and financing activities. It also includes explanations of these cash flow components and highlights key financial figures for the latest fiscal periods, such …

Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% Upside

Takeda Pharmaceutical Company Limited's average 12-month price target has been increased to $19.2, representing a potential 10% upside from its July 27 closing price. This revised target is based on estimates from 13 analysts, with forecasts ranging from $17.27 to $21.28 per share. The …

Stocks in play: Bausch Health Companies Inc.

Bausch Health Companies Inc. (T.BHC) announced that its PrELIDEL (pimecrolimus) cream is now approved for listing under Alberta's public drug plan for eligible patients. Following this announcement, the company's shares are trading up by $0.09 at $6.43.

United Therapeutics Number of Employees 2026 | Employee Count & Headcount Data

United Therapeutics Corp. (UTHR) had approximately 1,461 total employees worldwide as of March 2026, representing a 26.4% growth from 2023. The company is actively hiring with 158 active job postings in 2026, and its workforce is primarily concentrated in North America. Employee sentiment is …

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aurora Cannabis (ACB), Eli Lilly & Co (LLY) and Tyra Bioscience (TYRA)

This article summarizes recent analyst ratings for three healthcare stocks: Aurora Cannabis (ACB), Eli Lilly & Co (LLY), and Tyra Bioscience (TYRA). While Aurora Cannabis received a "Hold" rating from Roth MKM, with a C$4.00 price target, Eli Lilly & Co was rated "Buy" …

Alkermes plc Revenue Breakdown – NASDAQ:ALKS

Zoetis Inc (ZTS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Zoetis Inc (ZTS), outlining its major shareholders and institutional holdings. It provides a breakdown of individual shareholders and their proportions, categorizes shareholders by type, and presents institutional shareholding trends over several quarters. The report also lists recent …

(ALKS) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of Alkermes Plc (NASDAQ: ALKS), focusing on risk channels and responsive allocation strategies. It highlights strong near-term sentiment with a potential shift to long-term positive bias, noting a significant risk-reward short setup. The analysis outlines three specific trading …

Bausch Health Companies Inc.

Bausch Health Companies Inc. announced that its PrELIDEL® (pimecrolimus) cream has been listed under Alberta's public drug plan, making it available for eligible patients. Following this announcement, shares of Bausch Health Companies Inc. (T.BHC) saw an increase, trading up $0.09 at $6.43.

Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?

Supernus Pharmaceuticals (SUPN) is projected to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The company has an Earnings ESP of +18.52% and a Zacks Rank #3, indicating a high probability of beating the consensus EPS estimate …

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Alkermes (ALKS) reported revenue of $496.01 million, up 27% over the same period last year. EPS came in at $0, compared to $0.52 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $453.98 …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to join the investigation. …

Rubric Capital Management LP Acquires 421,347 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 12.7%, acquiring an additional 421,347 shares and now owning 3.75 million shares worth $180.6 million. This makes Kiniksa Pharmaceuticals the 12th biggest holding for Rubric, representing 1.9% of its investment …

(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis

LAVAL, QC, July 28, 2026 /PRNewswire/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients. ELIDEL® cream is indicated for second-line therapy …

Alkermes beats Q2 estimates, reaffirms revenue guidance

Alkermes plc reported strong second-quarter financial results, surpassing analyst expectations with adjusted earnings per share of $0.00 and revenue of $496.0 million, a 27% increase year-over-year. The company reaffirmed its full-year 2026 revenue guidance, citing strong performance across its proprietary product portfolio, particularly LUMRYZ, …

IM Cannabis Corp (IMCC) Institutional Confidence

This article focuses on the institutional confidence score for IM Cannabis Corp (IMCC) as of July 29, 2026. It presents a list of key shareholders and their holdings, including notable changes for Heron Bay Capital Management, LLC and BMO Nesbitt Burns Inc. The overall …

Lifecore Biomedical signs three new customer deals, boosting 2028 revenue outlook.

Lifecore Biomedical has secured three new customer agreements for early- and late-stage development programs, including a regenerative medicine project and a medical device formulation. These deals are expected to significantly contribute to the company's revenue growth by 2028. The agreements underscore Lifecore's broad technical …

EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - boerse.de

JPMorgan Chase & Co. has reported changes in its major holdings in Evotec SE, causing its total voting rights to exceed the 5% threshold. As of July 23, 2026, JPMorgan Chase & Co. holds 5.09% of voting rights, an increase from its previous notification …

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation …

Evolus Market Sentiment

This article analyzes market sentiment for Evolus (EOLS) through key signals like analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target significantly above the current stock price, despite some recent downgrades …

Teva Pharmaceutical Industries Ltd. $TEVA is Rubric Capital Management LP's 4th Largest Position

Rubric Capital Management LP reduced its stake in Teva Pharmaceutical Industries (TEVA) by 28.6% in the first quarter, though it remains their fourth-largest holding with a value of approximately $459.3 million. Despite this reduction, other institutional investors increased their positions, pushing overall institutional ownership …

Kiniksa (Nasdaq: KNSA) boosts 2026 ARCALYST sales view after strong Q2

Kiniksa Pharmaceuticals International reported strong second-quarter 2026 results, driven by its flagship therapy ARCALYST, leading to an increased 2026 net product revenue guidance of $980–$995 million for the drug. The company highlighted 55% year-over-year growth for ARCALYST, reaching $243.6 million in Q2, and noted …

Alkermes plc Reports Second Quarter 2026 Financial Results

DUBLIN, July 28, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a …

RedHill Biopharma (Nasdaq: RDHL) details opaganib plans amid Ebola surge

RedHill Biopharma has provided an update on its investigational antiviral opaganib for Ebola virus disease, amidst a growing outbreak of Bundibugyo ebolavirus with over 3,200 cases and 1,400 deaths by July 28, 2026. The company is actively discussing next-step planning and potential partnerships with …

Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline

Lifecore Biomedical (NASDAQ: LFCR) has announced three new customer agreements that will expand its pipeline in regenerative medicine and advanced medical technologies. These agreements include a late-stage regenerative medicine program and two early-stage programs focusing on formulation optimization, which are expected to contribute to …

Evotec SE Revenue Breakdown – SIX:EVT

Evotec SE (SIX:EVT) generated 734.07 million CHF in revenue last year. Its top-performing segment, Discovery & Preclinical Development, contributed 492.50 million CHF, a decrease from the previous year's 574.82 million CHF. The United States was the largest geographical contributor, accounting for 401.79 million CHF, …

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

Bausch + Lomb (BLCO) is set to report earnings tomorrow, with expectations for revenue growth of 7.2% year-on-year. The company has a strong record of beating revenue estimates, and analysts have reconfirmed their projections. Investors will be watching how BLCO performs compared to peers …

Evolus Inc (EOLS) Income Statement

This article provides the quarterly and annual income statement for Evolus Inc (EOLS), detailing key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, and net income. It allows users to gain insights into the company's financial performance and operational …

Evolus Inc (EOLS) Cash Flow

This article provides a detailed historical cash flow statement for Evolus Inc (EOLS), covering annual and quarterly data across various financial metrics like operating, investing, and financing cash flows. It includes period-over-period changes and absolute values for numerous line items, allowing for an in-depth …

Supernus Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:S49

Supernus Pharmaceuticals, Inc. (GETTEX:S49) generated 612.13 million EUR in revenue last year, primarily from its Central Nervous System Disease Treatments segment. The United States was the company's largest regional contributor to this revenue. This financial data shows a slight decrease from the previous year's …